BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Xeljanz (tofacitinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Xeljanz (tofacitinib)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07843693-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Xeljanz (tofacitinib): Phase 1 readout est. (NCT07843693)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 1.\nStudy: A Study to Evaluate th
 e Safety and Pharmacokinetics of Multiple Doses Upadacitinib\, Tofacitinib
 \, and Baricitinib in Healthy Adult Volunteers\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/to
 facitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07843693
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581418-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Xeljanz (tofacitinib): Phase na readout est. (NCT07581418)
DESCRIPTION:Xeljanz (tofacitinib)\, phase na.\nStudy: Comparison of Methotr
 exate and Tofacitinib in Chronic Plaque Psoriasis\nEstimated primary compl
 etion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tofacitinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07581418
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07055529-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Xeljanz (tofacitinib): Phase 1 readout est. (NCT07055529)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 1.\nStudy: Comparison of Efficacy
  and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in 
 the Treatment of Generalized Vitiligo.\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tofacit
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07055529
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131813-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Xeljanz (tofacitinib): Phase 4 readout est. (NCT07131813)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 4.\nStudy: Evaluation of Efficacy
  and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus\nEst
 imated primary completion: 1 January 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tofacitinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07131813
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06945666-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Xeljanz (tofacitinib): Phase 4 readout est. (NCT06945666)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 4\, Rheumatoid Arthritis.\nStudy:
  A Study of Iguratimod in Combination With Tofacitinib in RA Patients\nEst
 imated primary completion: 31 January 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tofacitinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06945666
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636057-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270305
DTEND;VALUE=DATE:20270306
SUMMARY:Xeljanz (tofacitinib): Phase 4 readout est. (NCT07636057)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 4\, Rheumatoid Arthritis.\nStudy:
  Comparison of Effectiveness and Safety of Tofacitinib Versus Upadacitinib
  as Add-on to Methotrexate in Rheumatoid Arthritis\nEstimated primary comp
 letion: 5 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tofacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07636057
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624230-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270317
DTEND;VALUE=DATE:20270318
SUMMARY:Xeljanz (tofacitinib): Phase 3 readout est. (NCT04624230)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: E
 valuation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering
  From Moderate to Severe Ulcerative Colitis\nEstimated primary completion:
  17 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tofac
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04624230
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07313072-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Xeljanz (tofacitinib): Phase 2 readout est. (NCT07313072)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 2.\nStudy: Topical Use of 2% Tofa
 citinib for Nail Psoriasis: an Exploratory Clinical Study\nEstimated prima
 ry completion: April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tofacitinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07313072
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07343635-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Xeljanz (tofacitinib): Phase na readout est. (NCT07343635)
DESCRIPTION:Xeljanz (tofacitinib)\, phase na.\nStudy: The Efficacy and Safe
 ty of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yello
 w Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adul
 t Patients With Mild to Moderate Erythematous Telangiectatic Rosacea\nEsti
 mated primary completion: 1 July 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/tofacitinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07343635
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06095128-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Xeljanz (tofacitinib): Phase 4 readout est. (NCT06095128)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 4\, Ulcerative Colitis.\nStudy: A
  Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (
 UC)\nEstimated primary completion: 9 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tofacitinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06095128
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925866-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Xeljanz (tofacitinib): Phase 2 readout est. (NCT07925866)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 2.\nStudy: Tislelizumab Combined 
 With Tofacitinib and Docetaxel for NSCLC After Failure of First-Line Immun
 otherapy\nEstimated primary completion: 30 August 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tofacitinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07925866
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660329-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Xeljanz (tofacitinib): Phase 4 readout est. (NCT06660329)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 4.\nStudy: Efficacy and Safety of
  Tofacitinib in Refractory Blau Syndrome\nEstimated primary completion: 1 
 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tofacit
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06660329
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07547930-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Xeljanz (tofacitinib): Phase 2 readout est. (NCT07547930)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 2.\nStudy: Tofacitinib for Glucoc
 orticoid-Resistant Moderate-to-Severe Thyroid Eye Disease\nEstimated prima
 ry completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tofacitinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07547930
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Xeljanz (tofacitinib): Phase 2 readout est. (NCT07138898)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 2.\nStudy: Immunosuppressant Mana
 gement in Rheumatology Patients Undergoing Elective Total Shoulder Arthrop
 lasty\nEstimated primary completion: January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/tofacitinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Xeljanz (tofacitinib): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 3\, Rheumatoid Arthritis.\nStudy:
  Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEs
 timated primary completion: March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tofacitinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04871191-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Xeljanz (tofacitinib): Phase 3 readout est. (NCT04871191)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 3.\nStudy: Study of Salvage Thera
 py to Treat Patients With Granulomatosis With Polyangiitis\nEstimated prim
 ary completion: October 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tofacitinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04871191
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06687551-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Xeljanz (tofacitinib): Phase 4 readout est. (NCT06687551)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 4\, Rheumatoid Arthritis.\nStudy:
  JAK Inhibitor Dose TAPering Strategy Study\nEstimated primary completion:
  1 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tofaci
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06687551
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06654882-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Xeljanz (tofacitinib): Phase 3 readout est. (NCT06654882)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 3.\nStudy: Trial of Sequential Me
 dications AfteR TNFi Failure in Juvenile Idiopathic Arthritis\nEstimated p
 rimary completion: 30 May 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tofacitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06654882
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522801-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Xeljanz (tofacitinib): Phase 2 readout est. (NCT07522801)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 2.\nStudy: A Precision Medicine T
 rial for Patients With Relapsed or Refractory T Cell ALL\nEstimated primar
 y completion: 1 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tofacitinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07522801
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Xeljanz (tofacitinib): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 4.\nStudy: Utilization of a Micro
 device for Psoriasis and Atopic Dermatitis\nEstimated primary completion: 
 1 June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tofaciti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07352566
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598643-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Xeljanz (tofacitinib): Phase 2 readout est. (NCT07598643)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 2.\nStudy: Modulation of the Immu
 ne System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1\
 nEstimated primary completion: August 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tofacitinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07598643
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281456-15@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20301215
DTEND;VALUE=DATE:20301216
SUMMARY:Xeljanz (tofacitinib): Phase 2 readout est. (NCT07281456)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 2.\nStudy: Safety of Tofacitinib\
 , an Oral Janus Kinase Inhibitor\, in Primary Sjogren Disease\nEstimated p
 rimary completion: 15 December 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tofacitinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07281456
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
